Skip to content

BPC-157

Early human Healing & Recovery In 5 protocols 3 sources

BPC-157 is a synthetic peptide sequence based on a protective compound naturally found in human gastric juice. Research suggests it has significant regenerative properties, promoting the healing of tendons, ligaments, muscles, and the gastrointestinal tract by accelerating angiogenesis and modulating growth factors.

01Dosing reference

Amount
250-500 mcg
Frequency
1-2 times daily
Cycle
4-6 weeks on, followed by 2-4 weeks off
Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

01

Angiogenesis Stimulation

BPC-157 upregulates vascular endothelial growth factor (VEGF) and other angiogenic pathways, promoting the formation of new blood vessels.

02

Fibroblast Activation

It accelerates the migration and proliferation of fibroblasts, which are crucial cells for synthesizing collagen and extracellular matrix in damaged tissues.

03

Tissue Regeneration

Enhanced blood flow and cellular repair mechanisms lead to accelerated healing of musculoskeletal injuries and protection of the gastric mucosa.

03Human evidence

Potential benefits in inflammatory bowel disease (IBD)

Early clinical observations and phase I/II trials have explored oral BPC-157 for ulcerative colitis, showing safety and potential mucosal healing, though large-scale phase III data is lacking.

Anecdotal and limited clinical reports of joint and tendon recovery

While widely used off-label by athletes for injury recovery, robust, peer-reviewed, large-scale human clinical trials specifically for musculoskeletal healing remain scarce.

04Preclinical evidence

Accelerated healing of transected Achilles tendons

In rat models, BPC-157 administration significantly improved the biomechanical properties and structural organization of healing tendons compared to controls.

Protection against NSAID-induced gastric ulcers

Animal studies demonstrate that BPC-157 can prevent and heal gastric lesions caused by non-steroidal anti-inflammatory drugs (NSAIDs) by maintaining mucosal integrity.

Enhanced muscle and nerve regeneration

Rodent models of crush injuries showed that BPC-157 promoted muscle healing and accelerated the recovery of peripheral nerve function.

05What is known vs. unknown

Reasonably established
  • Derived from a naturally occurring peptide found in human gastric juice.
  • Demonstrates potent angiogenic properties, stimulating the formation of new blood vessels to aid tissue repair.
  • Highly effective in animal models for healing tendons, ligaments, and muscles.
  • Shows significant gastroprotective effects, particularly against NSAID-induced damage in preclinical studies.
Unknowns & limits
  • Lack of large-scale, randomized, double-blind, placebo-controlled human trials for musculoskeletal injuries.
  • Long-term safety profile and potential risks of systemic angiogenesis stimulation in humans are not fully understood.
  • Optimal dosing protocols and delivery methods (oral vs. subcutaneous) for specific human conditions remain unstandardized.

06Safety & regulatory context

Regulatory statusBPC-157 is generally well-tolerated in animal studies with no reported lethal dose. However, its safety profile in humans is not fully established due to a lack of comprehensive clinical trials. Potential theoretical risks include the exacerbation of pre-existing conditions reliant on angiogenesis, such as certain tumors, though this has not been definitively proven. Regulatory status: BPC-157 is not approved by the FDA for human use and is banned by the World Anti-Doping Agency (WADA) under the category of unapproved substances. It is primarily available as a research chemical.

07Compared with TB-500 (Thymosin Beta-4)

Key difference
BPC-157 primarily acts through angiogenesis and gastrointestinal protection, while TB-500 focuses on actin upregulation and cellular migration.
When researchers discuss each
Researchers often discuss BPC-157 for localized tendon/ligament repair and gut health, whereas TB-500 is frequently explored for systemic muscle recovery and cardiovascular tissue repair. They are sometimes studied together for synergistic healing effects.

08Appears in protocols

09Glossary

Angiogenesis
The physiological process through which new blood vessels form from pre-existing vessels, essential for healing and tissue growth.
Fibroblast
A type of cell that synthesizes the extracellular matrix and collagen, playing a critical role in wound healing.
Gastric Mucosa
The mucous membrane layer of the stomach, which protects the organ from digestive acids and enzymes.

10Knowledge check

Q1What is the primary mechanism by which BPC-157 is believed to accelerate tissue healing?
Q2Where is the parent peptide of BPC-157 naturally found in the human body?
Q3Which statement best reflects the current state of human clinical evidence for BPC-157 in treating musculoskeletal injuries?
Q4When researchers compare BPC-157 with TB-500 (Thymosin Beta-4), which distinction aligns with the dossier's stated comparison context?
Q5Which regulatory and safety statement about BPC-157 is accurate according to the dossier?

11Sources

More in Healing & Recovery

See all
Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.